Autopsy report · NCT02649673

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

“Clinical program was discontinued by Novartis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 5 years 4 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

SCRI Development Innovations, LLC

Sponsor type

University, hospital or other

Conditions

Small Cell Lung Cancer; Ovarian Cancer

Interventions

LCL161; Topotecan; Pegylated GCSF (PEG-GCSF)

Participants

34

Sites

3

Countries

United States

Trials that died the same way

• Evaluation of MST-188 in Acute Lower Limb Ischemia
  “Program discontinued to persue alternate indications.” (67% match in meaning)
• RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
  “The sponsor's clinical program for the agent used in this study was discontinued.” (67% match in meaning)
• Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
  “UACC-PHX is no longer able to support the study and Novartis is unable to provide drug beyond December 2019.” (63% match in meaning)
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
  “Study discontinued due to futility.” (62% match in meaning)
• Medication Use Among American Indians Adults
  “The study has not been stopped. The study does not qualify as a clinical trial so it was withdrawn from clinicaltrials.gov.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.